Steroid 5alpha-reductase inhibitors in androgen-dependent disorders.
Inhibition of the steroid 5alpha-reductases shows promise in the treatment of a number of androgen-dependent disorders, such as benign prostatic hyperplasia, male pattern baldness, and acne. The design of potent and isozyme-selective inhibitors has provided biologists and clinicians with important tools for elucidating complex androgen physiology, and has already resulted in the development of one marketed drug.
Harris
G S
GS
Department of Biochemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA.
Kozarich
J W
JW
D058891:5-alpha Reductase Inhibitors; D000152:Acne Vulgaris / Q000188:drug therapy; D000505:Alopecia / Q000188:drug therapy; D000728:Androgens / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy
D058891:5-alpha Reductase Inhibitors; D000728:Androgens; D004791:Enzyme Inhibitors